Centauri
immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas
Centauri has raised €39M across 2 funding rounds from 3 investors, most recently a Series A round in Feb 2026. Based in London, UK; active in Healthtech. Data as of 28 Oct 2026.
London, UKwww.centauritherapeutics.com ↗
Total raised
€39M
€38,782,418
Funding rounds
2
Investors
3
distinct backers
Active since
2025-07
latest 2026-02
Funding by year
EUR raised per year · 2026 YTDCentauri — funding by year — interactive chart.
Data table
| Centauri — funding by year | |
|---|---|
| 2025 | €4.4M |
| 2026 | €34M |
Signals
High confidenceRaise-next likelihood46
base rate 44% for Series A
- ▼ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood16
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ Young (<3y)
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-02-24 | Series A | €34M | other investors,The AMR Action Fund | View deal → |
| 2025-07-29 | Other | €4.4M | Carb-X | View deal → |